Kaiser Family Foundation March 14, 2023

In anticipation of a ruling in a case with enormous implications for access to medication abortion in the United States, a new KFF brief explains the impact of this case, and others filed in federal courts, involving the FDA’s regulation of medication abortion. The case that has gotten the most attention recently is Alliance for Hippocratic Medicine (AHM) v. FDA, filed in November 2022, a challenge to the FDA’s decision to approve mifepristone (the first medication taken as part of the medication abortion drug regimen) and to include misoprostol in the medication abortion regimen. The outcome...

Today's Sponsors

LEK
Upfront Healthcare

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Patient / Consumer, Provider, Survey / Study, Trends
Related Articles:
Use AI to regulate AI, Google executive says
The Current State Of 521 FDA-Approved, AI-Based Medical Devices
Elon Musk’s Neuralink Wants To Put Chips In Our Brains — How It Works And Who Else Is Doing It
Over-the-Counter Hearing Aids — Using Regulatory Policy to Improve Public Health
FDA Updates Cybersecurity Guidance

Share This Article